Agile Therapeutics Stock Price, News & Analysis (NASDAQ:AGRX) $2.35 +0.05 (+2.17%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$2.25▼$2.4050-Day Range$1.75▼$2.6052-Week Range$1.65▼$16.00Volume35,422 shsAverage Volume54,796 shsMarket Capitalization$5.90 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Agile Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside261.7% Upside$8.50 Price TargetShort InterestHealthy0.76% of Float Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment0.37Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAgile Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Agile Therapeutics has a forecasted upside of 261.7% from its current price of $2.35.Amount of Analyst CoverageAgile Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.76% of the float of Agile Therapeutics has been sold short.Short Interest Ratio / Days to CoverAgile Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Agile Therapeutics has recently increased by 12.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgile Therapeutics does not currently pay a dividend.Dividend GrowthAgile Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agile Therapeutics is -1.59. Previous Next 1.9 News and Social Media Coverage News SentimentAgile Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agile Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agile Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.50% of the stock of Agile Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 7.52% of the stock of Agile Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Agile Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agile Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Agile Therapeutics Stock (NASDAQ:AGRX)Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.Read More AGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGRX Stock News HeadlinesDecember 4, 2023 | americanbankingnews.comHead-To-Head Comparison: Agile Therapeutics (NASDAQ:AGRX) & CytomX Therapeutics (NASDAQ:CTMX)December 3, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Research Coverage Started at StockNews.comDecember 8, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.December 2, 2023 | americanbankingnews.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Sees Significant Growth in Short InterestNovember 23, 2023 | msn.comAgile Therapeutics reports Q3 resultsNovember 21, 2023 | benzinga.comAgile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024November 11, 2023 | markets.businessinsider.comAgile Therapeutics: A Promising Investment with Positive Cash Flow Forecasts and Anticipated Growth in Twirla SalesNovember 10, 2023 | finance.yahoo.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call TranscriptDecember 8, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.November 9, 2023 | finance.yahoo.comAgile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 8, 2023 | msn.comAgile Therapeutics Q3 2023 Earnings PreviewOctober 26, 2023 | finance.yahoo.comAgile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023October 5, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)October 4, 2023 | finance.yahoo.comAgile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)September 30, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Upgraded To "Buy" Rating By Analysts At Maxim GroupSeptember 28, 2023 | finance.yahoo.comAgile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim GroupSeptember 27, 2023 | benzinga.comAgile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim GroupSeptember 5, 2023 | finance.yahoo.comAgile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 17, 2023 | msn.comAgile ($AGRX) Says It's On Track To Hit $25-$30M Net Annual Revenue After A Strong Performance In Q2August 11, 2023 | finance.yahoo.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | finance.yahoo.comAgile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 26, 2023 | finance.yahoo.comAgile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023July 19, 2023 | finance.yahoo.comThis Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With AfaxysJuly 18, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of WomenJuly 18, 2023 | msn.comNASDAQ: $AGRX Biden's Executive Order Boosts Adoption Of Agile Therapeutics' Contraceptive PatchJuly 14, 2023 | benzinga.comAgile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of WomenSee More Headlines Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+261.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($13.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,410,000.00 Net Margins-69.73% Pretax Margin-69.73% Return on EquityN/A Return on Assets-188.07% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.44 Sales & Book Value Annual Sales$10.88 million Price / Sales0.54 Cash FlowN/A Price / Cash FlowN/A Book Value($6.83) per share Price / Book-0.34Miscellaneous Outstanding Shares2,510,000Free Float2,499,000Market Cap$5.90 million OptionableNot Optionable Beta1.85 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Alfred F. Altomari (Age 64)Chairman, President & CEO Comp: $644.4kMr. Geoffrey P. Gilmore (Age 57)Senior VP & Chief Administrative Officer Comp: $478.92kDr. Paul Korner M.B.A. (Age 57)M.D., Senior VP & Chief Medical Officer Comp: $480.4kMr. Scott M. Coiante (Age 56)CFO, Senior VP & Treasurer Comp: $520.45kMatthew RileyHead of Investor Relations & Corporate CommunicationsMr. Robert G. Conway M.E. (Age 65)Senior VP and Chief Corporate Planning & Supply Chain Officer Comp: $444.11kMs. Amy Welsh (Age 52)Senior VP & Chief Commercial Officer Joseph D'UrsoControllerMore ExecutivesKey CompetitorsBiofronteraNASDAQ:BFRIChemomab TherapeuticsNASDAQ:CMMBGraybug VisionNASDAQ:GRAYHoth TherapeuticsNASDAQ:HOTHLucy Scientific DiscoveryNASDAQ:LSDIView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 24,000 shares on 11/15/2023Ownership: 5.078%View All Institutional Transactions AGRX Stock Analysis - Frequently Asked Questions Should I buy or sell Agile Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks. What is Agile Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 1 year price targets for Agile Therapeutics' stock. Their AGRX share price targets range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $8.50 in the next year. This suggests a possible upside of 261.7% from the stock's current price. View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts. How have AGRX shares performed in 2023? Agile Therapeutics' stock was trading at $0.2270 at the beginning of the year. Since then, AGRX shares have increased by 935.2% and is now trading at $2.35. View the best growth stocks for 2023 here. Are investors shorting Agile Therapeutics? Agile Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 18,000 shares, an increase of 12.5% from the October 31st total of 16,000 shares. Based on an average daily volume of 40,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.8% of the shares of the stock are sold short. View Agile Therapeutics' Short Interest. When is Agile Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our AGRX earnings forecast. How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported ($1.47) earnings per share for the quarter. The specialty pharmaceutical company earned $6.66 million during the quarter. When did Agile Therapeutics' stock split? Agile Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has Agile Therapeutics issued on next quarter's earnings? Agile Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00M-, compared to the consensus revenue estimate of $21.66 million. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX). Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (5.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Agile Therapeutics? Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AGRX) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.